Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference

Lundbeck presented six-month, real-world interim data from the 12-month INFUSE study (n=111) showing IV eptinezumab (Vyepti) produced clinically meaningful improvements in adults who previously failed ≥1 preventive aCGRP: 75.7% reported any improvement on PGIC (95% CI 66.9–82.7%), 44.1% reported “much”/“very much” improved (95% CI 35.3–53.4%), a mean reduction of 6.8 monthly headache days from a 20.0 baseline (95% CI 5.2–8.3), 44.1% achieved ≥50% MHD reduction, and 26.1% achieved >75% reduction; patients also reported +6.3 “good days”/month. The observational findings, while limited by sample size and lack of in-study safety collection, reinforce earlier trial efficacy and could support earlier use and commercial uptake of Vyepti across markets where it is approved.

Analysis

Market structure: Lundbeck (LUN.CO) is the direct beneficiary—INFUSE RWE shows ~44% ≥50% MHD reduction at 6 months in a refractory group, which can translate to a focused pricing/prescribing advantage in the high-burden chronic-migraine cohort (estimate: 5–15% share migration within this segment over 12–24 months). Outpatient infusion providers (home/ASC operators) also win as IV administration creates incremental demand; incumbent SC aCGRP makers (large-cap franchises) face modest volume pressure but not immediate pricing collapse. On supply/demand, expect near-term infusion-capacity tightness in top US MSAs and steady manufacturing demand for monoclonals; credit spreads for specialty pharma may tighten slightly on better visibility.

Risks: Tail risks include payer non-coverage/step-edit policies and a late safety signal (hypersensitivity) that could force label changes—both have low probability but high impact on uptake and valuation. Time horizons: days — limited market reaction to the poster; 1–6 months — payer coverage decisions and additional RWE; 6–36 months — realized market-share and revenue. Hidden dependencies: adoption hinges on contracts with infusion networks, CMS/MA coverage policies, and the small INFUSE sample (n=111) may overstate effect sizes. Catalysts: upcoming payer guidance, Lundbeck sales cadence, and additional INFUSE/real-world readouts.

Trade implications: Core tactically long Lundbeck (LUN.CO) 2–3% position with 6–12 month horizon, stop-loss −15%, take-profit +25%; hedge with a 6–9 month call spread ~20–30% OTM sized 1–1.5% to limit capital. Play ancillary demand by adding 1–2% long exposure to US outpatient infusion operator Option Care Health (OPCH) or healthcare-services ETF (XHE) for 6–12 months. Consider a small pair (long LUN.CO, short AMGN 1%) over 6–12 months as a relative-value trade if you believe niche IV advantage will win share among refractory patients.

Contrarian angle: The market may overreact to a small, uncontrolled RWE cohort—n=111 and selection via infusion partners creates upward bias; convenience and payer resistance often limit IV uptake versus SC despite efficacy claims. Historical parallels: hospital-administered biologics sometimes fail to displace convenient self-injectables beyond severe subgroups. Therefore keep positions size-limited, prefer option-defined exposure, and reduce risk if CMS/major PBM step-edit appears within 30–90 days.

Key Decisions for Investors

• Establish a 2–3% long position in H. Lundbeck (LUN.CO) with a 6–12 month horizon; set an initial stop-loss at −15% and take-profit at +25%; re-evaluate on the next INFUSE 12-month readout or major payer coverage decisions (target timeline: 3–6 months).
• Buy a 6–9 month call spread on LUN.CO ~20–30% OTM sized at 1–1.5% of portfolio to capture upside with defined risk if real-world uptake outperforms; close if implied vol rises >30% or spread cost exceeds 70 bps of notional premium.
• Add 1–2% long exposure to outpatient infusion operators (Option Care Health, OPCH, or sector ETF XHE) for 6–12 months to play increased infusion demand; take profits if utilization indicators (infusion center booking rates) do not improve within 90 days.
• Initiate a small pair trade: long LUN.CO 1–2% and short AMGN (AMGN) 1% for 6–12 months as a relative-value play on IV switching in refractory patients; unwind immediately if major PBMs/CMS issue step-edit policies within 30–90 days or if new safety signals emerge.